There has been an intense interest in developing novel therapeutic strategies to target HIF-1α in cancer therapy for the following reasons: (1) HIF-1α expression has been found high in the majority of tumors, especially solid tumor, because of hypoxia, (2) HIF-1 is a master regulator for many aspects in cancer biology, and (3) inhibition of HIF-1α may exploit tumor hypoxia by converting it from a treatment obstacle into a targeting advantage. Here, HIF1A is linked to cancer.